Abstract
Objective: Ovarian carcinoma is a malignant tumor with the highest mortality of any cancer occurring in female reproductive system. Cytoreductive surgery is the main treatment for ovarian cancer and has markedly improved. Mechanism: This article discusses the evolution and development of ovarian cancer cytoreductive surgery (CRS), including classical standard tumor cell reduction, visceral-peritoneal debulking (VPD) and ultra-radical cytoreduction (URC). Findings in Brief: we reviewed CRS in combination with radiotherapy, chemotherapy and immunotherapy for ovarian cancer (OC). Finally, we discussed the opportunity and challenges of ROC therapeutic. Conclusions: This study reveals that CRS and combination therapy can help clinicians to find the optimum treatment for ovarian cancer (OC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical and Experimental Obstetrics & Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
